| (Values in U.S. Thousands) | Oct, 2025 | Oct, 2024 | Oct, 2023 | Oct, 2022 | Oct, 2021 |
| Sales | 0 | 0 | 210 | 0 | 510 |
| Sales Growth | unch | -100.00% | unch | -100.00% | unch |
| Net Income | -10,930 | -12,550 | -9,810 | -13,600 | -12,950 |
| Net Income Growth | +12.91% | -27.93% | +27.87% | -5.02% | -29.24% |
Anixa Biosciences Inc (ANIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Anixa Biosciences, Inc. operates as a bio-technology company. It develops diagnostics and therapeutics to detect cancer. Anixa Biosciences Inc., formerly known as ITUS Corporation, is based in San Jose, United States.
Fiscal Year End Date: 10/31